Lee Hyo-Jung, Cho Hyun-Soo, Jun Soo Young, Lee Jeong-Ju, Yoon Ji-Yong, Lee Jae-Hye, Song Hyuk-Hwan, Choi Sang Ho, Kim Soo-Yong, Saloura Vassiliki, Park Choon Gil, Kim Nam-Soon
Medical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-333, Republic of Korea.
Natural Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-333, Republic of Korea.
Oncol Rep. 2014 Sep;32(3):1117-23. doi: 10.3892/or.2014.3279. Epub 2014 Jun 23.
Induction of apoptosis through activation of the TRAIL pathway is considered to be a promising anticancer strategy due to its ability to selectively induce apoptosis in cancer cells. However, the ability of cancer cells to acquire TRAIL resistance has limited the clinical translation of this approach. We previously reported that the TOR signaling pathway regulator-like (TIPRL) protein contributes to the resistance to TRAIL-induced apoptosis by inhibiting the MKK7-c-Jun N-terminal kinase (JNK) pathway via MKK7‑TIPRL interaction. In the present study, we identified Tussilago farfara L. (TF) as a novel TRAIL sensitizer among 500 natural products using an ELISA system that specifically detects the MKK7-TIPRL interaction, and we validated candidates by GST-pull down assay. Co-treatment of Huh7 cells with TF and TRAIL induced apoptosis via inhibition of the MKK7-TIPRL interaction and an increase in MKK7/JNK phosphorylation. This is the first report to describe TF as a novel TRAIL sensitizer, unveiling a potentially novel therapeutic strategy in cancer therapy.
通过激活TRAIL途径诱导细胞凋亡被认为是一种很有前景的抗癌策略,因为它能够选择性地诱导癌细胞凋亡。然而,癌细胞获得TRAIL抗性的能力限制了这种方法的临床应用。我们之前报道过,TOR信号通路调节样(TIPRL)蛋白通过MKK7-TIPRL相互作用抑制MKK7-c-Jun氨基末端激酶(JNK)途径,从而导致对TRAIL诱导的细胞凋亡产生抗性。在本研究中,我们使用一种专门检测MKK7-TIPRL相互作用的ELISA系统,在500种天然产物中鉴定出款冬(TF)是一种新型TRAIL增敏剂,并通过谷胱甘肽S-转移酶(GST)下拉实验验证了候选物。TF与TRAIL联合处理Huh7细胞,通过抑制MKK7-TIPRL相互作用以及增加MKK7/JNK磷酸化诱导细胞凋亡。这是首次报道将TF描述为新型TRAIL增敏剂,揭示了癌症治疗中一种潜在的新型治疗策略。